中文摘要：

目的检测循环miR-128在结直肠癌患者血清中的表达,观察其对结直肠癌细胞迁移侵袭能力的影响。方法选择2012年6月至12月在山东大学齐鲁医院行结直肠癌根治术的结直肠癌患者57例（结直肠癌组,又分为转移组和未转移组）,以健康查体的志愿者20例（健康对照组）为参照。实时荧光定量PCR法检测两组血清中miR-128的表达,分析其与结直肠癌转移的关系;采用Lipofectamine 2000将miR-128模拟物转染入HT-29细胞,观察miR-128过表达对HT-29细胞迁移侵袭能力的影响。结果结直肠癌组血清miR-128水平明显低于健康对照组（P〈0.001）,其中转移组水平明显低于未转移组（P=0.014）。ROC曲线分析显示,血清miR-128对诊断结直肠癌和转移鉴别诊断的效能分别为0.85、0.71（P均〈0.05）。miR-128过表达使HT-29细胞迁移愈合率以及迁移、侵袭细胞数明显减少。结论循环miR-128在结直肠癌患者血清中表达明显下调,并且与转移密切相关,为结直肠癌转移诊断和治疗提供了新思路。

英文摘要：

Objective To detect the expression of miR-128 in the serum of patients with colorectal cancer and to observe its effect on the migration and invasion of colorectal cancer cells. Methods A total of 57 cases of colorectal cancer patients receiving colorectal cancer resection from June to December 2012（ colorectal cancer group,further classified in to metastasis group and non-metastasis group） were selected from Qilu hospital of Shandong University,and 20 cases of volunteer with health checkup（ healthy control group） were as reference. The serum miR-128 levels were detected by quantitative real-time PCR between two groups,and its relationship with metastasis was analyzed. MiR-128 mimics were transfected into HT-29 cells using Lipofectamine 2000 to observe affection of miR-128 overexpression on migration and invasion ability of HT-29 cells. Results The miR-128 expression in colorectal cancer group was significantly lower than that in healthy control group（ P〈0. 001）,and it markedly decreased in the metastasis group compared with non-metastasis group（ P = 0. 014）. The diagnosis and metastasis differential diagnosis capabilities of serum miR-128 for colorectal cancer were 0. 85 and 0. 71（ both P〈0. 05）. Overexpression of miR-128 made the migration healing rates and number of migration and invasion cells of HT-29 cells significantly reduced. Conclusion Circulating miR-128 is significantly decreased in serum of colorectal cancer and closely associated with colorectal cancermetastasis,which may provide a new idea for the diagnosis and therapy of colorectal cancer.